300 related articles for article (PubMed ID: 24096963)
1. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
2. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Alendronate Loaded Biphasic Calcium Phosphate Scaffolds on Bone Regeneration in a Rat Tibial Defect Model.
Park KW; Yun YP; Kim SE; Song HR
Int J Mol Sci; 2015 Nov; 16(11):26738-53. PubMed ID: 26561810
[TBL] [Abstract][Full Text] [Related]
4. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
5. Serial administration of rhBMP-2 and alendronate enhances the differentiation of osteoblasts.
Kim SH; Choi HJ; Yoon DS; Son CN
Int J Rheum Dis; 2021 Oct; 24(10):1266-1272. PubMed ID: 34324274
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
[TBL] [Abstract][Full Text] [Related]
7. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
8. Local delivery of alendronate eluting chitosan scaffold can effectively increase osteoblast functions and inhibit osteoclast differentiation.
Kim SE; Suh DH; Yun YP; Lee JY; Park K; Chung JY; Lee DW
J Mater Sci Mater Med; 2012 Nov; 23(11):2739-49. PubMed ID: 22850978
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous delivery of BMP-2 factor and anti-osteoporotic drugs using hyaluronan-assembled nanocomposite for synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro.
Zhang Y; Hu Y; Luo Z; Shen X; Mu C; Cai K
J Biomater Sci Polym Ed; 2015; 26(5):290-310. PubMed ID: 25585099
[TBL] [Abstract][Full Text] [Related]
10. Effects of alendronate on osteoclast formation and activity in vitro.
Martins CA; Leyhausen G; Volk J; Geurtsen W
J Endod; 2015 Jan; 41(1):45-9. PubMed ID: 25442070
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells.
Xiong Y; Yang HJ; Feng J; Shi ZL; Wu LD
J Int Med Res; 2009; 37(2):407-16. PubMed ID: 19383235
[TBL] [Abstract][Full Text] [Related]
12. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Hayami T; Pickarski M; Wesolowski GA; McLane J; Bone A; Destefano J; Rodan GA; Duong LT
Arthritis Rheum; 2004 Apr; 50(4):1193-206. PubMed ID: 15077302
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
14. Alendronate alters osteoblast activities.
Krüger TB; Herlofson BB; Landin MA; Reseland JE
Acta Odontol Scand; 2016 Oct; 74(7):550-557. PubMed ID: 27546224
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.
Zhang J; Park J; Lee JW; Kwon YD; Kim EC
Clin Oral Investig; 2018 Jun; 22(5):1933-1943. PubMed ID: 29188452
[TBL] [Abstract][Full Text] [Related]
16. Immobilization of alendronate on titanium via its different functional groups and the subsequent effects on cell functions.
Zheng D; Neoh KG; Kang ET
J Colloid Interface Sci; 2017 Feb; 487():1-11. PubMed ID: 27743540
[TBL] [Abstract][Full Text] [Related]
17. Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts.
Zhai Y; Li Y; Wang Y; Cui J; Feng K; Kong X; Chen L
Eur J Pharmacol; 2017 Apr; 801():62-71. PubMed ID: 28283388
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.
Giannasi C; Niada S; Farronato D; Lombardi G; Manfredi B; Farronato G; Brini AT
Int J Med Sci; 2019; 16(1):23-32. PubMed ID: 30662325
[TBL] [Abstract][Full Text] [Related]
19. Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis.
Patntirapong S; Singhatanadgit W; Arphavasin S
J Clin Pharm Ther; 2014 Aug; 39(4):349-53. PubMed ID: 24661151
[TBL] [Abstract][Full Text] [Related]
20. [Effect of the bone resorption supernatant from RAW264.7 osteoclast on the osteogenic activity of mouse MC3T3-E1 cell].
Chen LL; Wang K; Zhang J; Wu YM
Zhonghua Kou Qiang Yi Xue Za Zhi; 2012 Jan; 47(1):32-7. PubMed ID: 22490219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]